Cercar
15/09/2025
Reduced circulating levels of CXCL14 are associated with cardiovascular damage in people living with HIV
Quesada-López, T, Mestres-Arenas, A, Domingo, P, Prieto, P, Mur, I, Pérez, JAH, Guimaraes, MP, Villarroya, J, Gutiérrez, MD, Mateo, MG, Domingo, JC, Planavila, A, Villarroya, F, Giralt, M, Cereijo, R. Reduced circulating levels of CXCL14 are associated with cardiovascular damage in people living with HIV. EUROPEAN JOURNAL OF PHARMACOLOGY. 2025; 1003DOI:10.1016/j.ejphar.2025.177996. PMID:40714072. IF:4.700(Q1/2D).
03/10/2023
Decay of HIV RNA in Seminal Plasma and Rectal Fluid in Treatment-Naive Adults Starting Antiretroviral Therapy With Dolutegravir Plus Lamivudine or Bictegravir/Emtricitabine/Tenofovir Alafenamide.
Scévola S, Niubó J, Domingo P, Verdejo G, Curran A, Diaz-Brito V, Peñafiel J, Tiraboschi J, Morenilla S, Garcia B, Soriano I, Podzamczer D, Imaz A. Decay of HIV RNA in Seminal Plasma and Rectal Fluid in Treatment-Naive Adults Starting Antiretroviral Therapy With Dolutegravir Plus Lamivudine or Bictegravir/Emtricitabine/Tenofovir Alafenamide.. JOURNAL OF INFECTIOUS DISEASES. 2023; 228(7)DOI:10.1093/infdis/jiad304. PMID:37526315. IF:(Q/D).
05/09/2023
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir.
González-Cordón A, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Stellbrink HJ, Guaraldi G, Masiá M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Behrens G, Pozniak A, Gatell JM, Martínez E. Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir.. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2023; 78(9)DOI:10.1093/jac/dkad247. PMID:37539492. IF:3.900(Q1/3D).
01/10/2023
Gene therapy restores the transcriptional program of hematopoietic stem cells in Fanconi anemia.
Lasaga M, Río P, Vilas-Zornoza A, Planell N, Navarro S, Alignani D, Fernández-Varas B, Mouzo D, Zubicaray J, Pujol RM, Nicoletti E, Schwartz JD, Sevilla J, Ainciburi M, Ullate-Agote A, Surrallés J, Perona R, Sastre L, Prosper F, Gomez-Cabrero D, Bueren JA. Gene therapy restores the transcriptional program of hematopoietic stem cells in Fanconi anemia.. HAEMATOLOGICA. 2023; 108(10)DOI:10.3324/haematol.2022.282418. PMID:37021532. IF:10.100(Q1/2D).
12/02/2024
The role of sex and gender in the diagnosis and treatment of lung cancer: the 6th ICAPEM Annual Symposium.
Viñolas N, Mezquita L, Corral J, Cobo M, Gil-Moncayo F, Paz-Ares L, Remon J, Rodríguez M, Ruano-Raviña A, Conde E, Majem M, Garrido P, Felip E, Isla D, de Castro J. The role of sex and gender in the diagnosis and treatment of lung cancer: the 6th ICAPEM Annual Symposium.. Clinical & Translational Oncology. 2024; 26(2)DOI:10.1007/s12094-023-03262-x. PMID:37490262. IF:2.500(Q3/6D).
01/12/2023
Survival Differences of Patients with Resected Extraskeletal Osteosarcoma Receiving Two Different (Neo)Adjuvant Chemotherapy Regimens: A Systematic Review and Meta-analysis.
Campos F, Téres R, Sebio A, Bettim BB, Martinez-Trufero J. Survival Differences of Patients with Resected Extraskeletal Osteosarcoma Receiving Two Different (Neo)Adjuvant Chemotherapy Regimens: A Systematic Review and Meta-analysis.. CLINICAL ONCOLOGY. 2023; 35(12)DOI:10.1016/j.clon.2023.09.009. PMID:37777356. IF:3.200(Q2/5D).
01/10/2023
Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05).
Nadal E, Rodríguez-Abreu D, Simó M, Massutí B, Juan O, Huidobro G, López R, De Castro J, Estival A, Mosquera J, Sullivan I, Felip E, Blasco A, Guirado M, Pereira E, Vilariño N, Navarro V, Bruna J. Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05).. JOURNAL OF CLINICAL ONCOLOGY. 2023; 41(28)DOI:10.1200/JCO.22.02561. PMID:37603816. IF:42.100(Q1/1D).
01/09/2023
Prehabilitation in Patients With Breast Cancer Receiving Neoadjuvant Therapy to Minimize Musculoskeletal Postoperative Complications and Enhance Recovery (PREOPtimize): A Protocol for a Randomized Controlled Trial.
Casanovas-Álvarez A, Sebio-Garcia R, Ciendones M, Cuartero J, Estanyol B, Padrós J, García-Valdecasas B, Barnadas A, Masia J. Prehabilitation in Patients With Breast Cancer Receiving Neoadjuvant Therapy to Minimize Musculoskeletal Postoperative Complications and Enhance Recovery (PREOPtimize): A Protocol for a Randomized Controlled Trial.. PHYSICAL THERAPY. 2023; 103(9)DOI:10.1093/ptj/pzad062. PMID:37318267. IF:3.500(Q1/1D).